The ASCO Post

Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes

A long-term follow-up of the phase III UK IMPORT LOW trial has shown that partial-breast and reduced-dose radiotherapy continue to be associated with similar ipsilateral breast tumor recurrence outcomes compared with whole-breast radiotherapy in patients with low-risk early-stage breast cancer.

Addition of Retifanlimab to First-Line Chemotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal

In a phase III trial (POD1UM-303/InterAACT-2), researchers investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML

Investigators examined whether triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor are active in intensive chemotherapy-ineligible patients with IDH-mutant AML.

Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers

Two oncologists highlight the most impactful updates in genitourinary tumors from the 2025 ASCO Annual Meeting.

ASTRO Updates Guideline on Radiation Therapy for High-Grade Diffuse Glioma

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy for adults with WHO grade 4 diffuse gliomas, a category that includes some of the most common and most aggressive primary brain tumors.

Study Finds About One in Six Chemotherapy Drugs in Sub-Saharan Africa Fails Quality Tests

"Oncology practitioners and health systems in sub-Saharan Africa need to be aware of the possible presence of substandard anticancer products when designing care protocols and evaluating patient outcomes, and regulatory system strengthening is needed to provide better surveillance of this crucial class of medicines."